TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$1.62 USD
-0.12 (-6.90%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.62 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TCRX 1.62 -0.12(-6.90%)
Will TCRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
TCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
Other News for TCRX
Tracking Baker Brothers Portfolio - Q1 2025 Update
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)
Morgan Stanley Keeps Their Buy Rating on TScan Therapeutics (TCRX)
TScan Therapeutics management to meet virtually with BTIG
TCRX: Upcoming Virtual Meeting Scheduled for May 15 | TCRX Stock News